Overview

Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

Summary

Trial to evaluate steady state pharmacokinetic parameters of nevirapine 150mg/m2 and nevirapine 4 or 7 mg/kg after 4 weeks, and efficacy and safety of the dosing when administered for 48 weeks in antiretroviral drug naïve paediatric patients.

Phase:

Phase 2

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Lamivudine
Nevirapine
Zidovudine